Biolase (NASDAQ:BIOL) Receiving Somewhat Favorable News Coverage, Report Shows

News articles about Biolase (NASDAQ:BIOL) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biolase earned a news impact score of 0.09 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next few days.

Shares of Biolase (BIOL) traded down 5.62% during mid-day trading on Friday, reaching $0.84. The company had a trading volume of 67,802 shares. Biolase has a one year low of $0.79 and a one year high of $1.98. The firm’s market capitalization is $56.83 million. The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.25.

Biolase (NASDAQ:BIOL) last issued its quarterly earnings results on Wednesday, May 3rd. The medical technology company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by $0.03. The firm had revenue of $10.87 million for the quarter. Biolase had a negative net margin of 29.44% and a negative return on equity of 65.77%. Equities analysts predict that Biolase will post ($0.14) EPS for the current year.

Several research firms have commented on BIOL. Singular Research began coverage on Biolase in a report on Tuesday, April 25th. They issued a “buy” rating and a $2.50 price target for the company. ValuEngine lowered Biolase from a “hold” rating to a “sell” rating in a research report on Monday, July 24th.

WARNING: “Biolase (NASDAQ:BIOL) Receiving Somewhat Favorable News Coverage, Report Shows” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/07/29/biolase-nasdaqbiol-getting-somewhat-positive-media-coverage-report-shows-updated-updated-updated.html.

About Biolase

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Insider Buying and Selling by Quarter for Biolase (NASDAQ:BIOL)

Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply